Track topics on Twitter Track topics that are important to you
We list hundreds of Clinical Trials about "Plexxikon Inc." on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
We have published hundreds of Plexxikon Inc. news stories on BioPortfolio along with dozens of Plexxikon Inc. Clinical Trials and PubMed Articles about Plexxikon Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Plexxikon Inc. Companies in our database. You can also find out about relevant Plexxikon Inc. Drugs and Medications on this site too.
This open-label single arm study will assess the efficacy, safety and tolerability of RO5185426 in previously treated patients with metastatic melanoma. Patients will receive oral RO5185426 [RG7204; PLEXXIKON: PLX4032] at a dose of 960 mg b.i.d. continuously until disease progression or withdrawal from study and will be assessed at regular intervals for tumour response and tolerability. Target sample size is